Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT03216148 : 18F-FET PET in Childhood Brain Tumours
PhasePhase 2
AgesMin: 1 Year Max: 17 Years
Inclusion Criteria:

- Written informed consent (given by the parents as legal representatives of the
patients and given by the patients)

- Completion of the first line therapy according to the current HIT-protocols (Current
and subsequent paediatric primary brain tumour treatment studies approved by GPOH)

- Fully evaluable MRI at the end of first line therapy as confirmed by the reference
centre of neuroradiology (Prof. Dr. M. Warmuth-Metz, Würzburg)

- Histology of primary brain tumour confirmed by local and reference centre of
Neuropathology (Prof. Dr. T. Pietsch) except for patients where tumour diagnosis is
confirmed by the reference centre of neuroradiology, i.e. NF-1 and confirmed LGG or
patient with diffuse intrinsic pontine glioma

- Laboratory requirements prior to enrolment: Serum creatinine: within normal limits;
AST, ALT: not more than 10 x above normal limits

- Age at inclusion: 1 year to 17 years

- Children below the age of 12 years are included as 2 of 3 paediatric patients with a
brain tumour are younger than 12 years. Furthermore, young age is a known negative
risk factor for different histological entities. Thus, this group is the most likely
to benefit from the results of this study

- In all patients with reproductive potential, a pregnancy must be excluded by a
pregnancy test before FET PET investigation

- Highly effective contraception in women with reproductive potential (defined as pearl
index < 1) during study participation and follow up time

- No participation in other clinical trials according to AMG with the same clinical
indication over the course of the FET PET 2010 study

Exclusion Criteria:

- Presence of solid non-CNS tumours or leukaemia

- MRI at completion of first line therapy that does not meet standard quality criteria
for evaluation as defined by the reference centre for neuroradiology of the
HITNetzwerk (Würzburg, Prof. Warmuth-Metz);

- Known allergic reactions or drug intolerance to contrast agents

- Patients according to § 88 StrhlSchV

- Pregnancy or breast-feeding

- Women (adolescents) of childbearing potential without highly effective contraception
(PEARL-Index < 1%), for example ParaGard IntraUterineDevice (IUD), Mirena IUD,
Implants, Depo Provera Injections;

- Persons who are detained officially or legally to an official institute
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557